The FDA has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy, Aldeyra Therapeutics announced in a press release.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
